dc.contributor.author |
Jimenez, Amanda |
dc.contributor.author |
Pegueroles, Jordi |
dc.contributor.author |
Carmona Iragui, María |
dc.contributor.author |
Vilaplana, Eduard |
dc.contributor.author |
Montal, Victor |
dc.contributor.author |
Alcolea, Daniel |
dc.contributor.author |
Videla Toro, Laura |
dc.contributor.author |
Illán-Gala, Ignacio |
dc.contributor.author |
Pané, Adriana |
dc.contributor.author |
Casajoana, Anna |
dc.contributor.author |
Belbin, Olivia |
dc.contributor.author |
Clarimón, Jordi |
dc.contributor.author |
Moizé, Violeta |
dc.contributor.author |
Vidal, Josep |
dc.contributor.author |
Lleó, Alberto |
dc.contributor.author |
Fortea, Juan |
dc.contributor.author |
Blesa, Rafael |
dc.contributor.author |
Universitat Autònoma de Barcelona |
dc.date |
2017 |
dc.identifier |
https://ddd.uab.cat/record/186403 |
dc.identifier |
urn:10.18632/oncotarget.22218 |
dc.identifier |
urn:oai:ddd.uab.cat:186403 |
dc.identifier |
urn:pmid:29285207 |
dc.identifier |
urn:pmcid:PMC5739594 |
dc.identifier |
urn:pmc-uid:5739594 |
dc.identifier |
urn:articleid:19492553v8p104706 |
dc.identifier |
urn:scopus_id:85036514944 |
dc.identifier |
urn:wos_id:000419563600002 |
dc.identifier |
urn:altmetric_id:31181030 |
dc.identifier |
urn:oai:egreta.uab.cat:publications/77155daa-f59d-4743-946b-391b288d517c |
dc.identifier |
urn:oai:pubmedcentral.nih.gov:5739594 |
dc.format |
application/pdf |
dc.language |
eng |
dc.publisher |
|
dc.relation |
Instituto de Salud Carlos III FIS-PI14-00336 |
dc.relation |
Agència de Gestió d'Ajuts Universitaris i de Recerca 2014 SGR 530 |
dc.relation |
Oncotarget ; Vol. 8 (october 2017), p. 104706-104716 |
dc.rights |
open access |
dc.rights |
Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original. |
dc.rights |
https://creativecommons.org/licenses/by/3.0/ |
dc.subject |
Pre-clinical Alzheimer's disease |
dc.subject |
Weight loss |
dc.subject |
Cerebrospinal fluid Alzheimer's disease biomarkers |
dc.subject |
PET amyloid |
dc.subject |
Magnetic resonance imaging |
dc.subject |
Gerotarget |
dc.title |
Weight loss in the healthy elderly might be a non-cognitive sign of preclinical Alzheimer's disease |
dc.type |
Article |
dc.description.abstract |
Weight loss has been proposed as a sign of pre-clinical Alzheimer Disease (AD). To test this hypothesis, we have evaluated the association between longitudinal changes in weight trajectories, cognitive performance, AD biomarker profiles and brain structure in 363 healthy controls from the Alzheimer's Disease Neuroimaging Initiative (mean follow-up 50.5±30.5 months). Subjects were classified according to body weight trajectory into a weight loss group (WLG; relative weight loss ≥ 5%) and a non-weight loss group (non-WLG; relative weight loss < 5%). Linear mixed effects models were used to estimate the effect of body weight changes on ADAS-Cognitive score across time. Baseline CSF tau/AΔ ratio and AV45 PET uptake were compared between WLG and non-WLG by analysis of covariance. Atrophy maps were compared between groups at baseline and longitudinally at a 2-year follow-up using Freesurfer. WLG showed increased baseline levels of cerebrospinal fluid tau/AΔ ratio, increased PET amyloid uptake and diminished cortical thickness at baseline. WLG also showed faster cognitive decline and faster longitudinal atrophy. Our data support weight loss as a non-cognitive manifestation of pre-clinical AD. |